Cephalexin Use in Elderly Patients
Cephalexin can be safely used in elderly patients at standard adult doses (1-4 g daily in divided doses) with mandatory dose reduction only when creatinine clearance falls below 30 mL/min, though careful monitoring is essential given age-related renal decline. 1
Standard Dosing in Elderly
The FDA-approved adult dosing applies to elderly patients with preserved renal function 1:
- Standard dose: 250 mg every 6 hours
- Alternative regimen: 500 mg every 12 hours for streptococcal pharyngitis, skin infections, and uncomplicated cystitis
- Maximum: 4 g daily (higher doses require parenteral cephalosporins)
Clinical evidence supports this approach—a study of 298 elderly patients demonstrated 93% satisfactory response in respiratory infections, 96% in skin/soft tissue infections, and 87% in urinary tract infections, with only 7% experiencing mild adverse reactions 2. A separate multicenter trial of 194 vulnerable elderly patients showed over 80% cure or improvement rates with 1-2 g daily dosing 3.
Critical Renal Function Assessment
The key pitfall in elderly prescribing is that normal serum creatinine does not equal normal renal function. Elderly patients commonly have reduced muscle mass, masking significant GFR decline 4, 1. You must calculate creatinine clearance or eGFR—approximately 26% of patients over 70 have chronic kidney disease despite normal-appearing creatinine 4.
Dose Adjustment Algorithm
Cephalexin is 70-100% renally excreted unchanged, with elimination half-life increasing from 58 minutes (normal function) to 15.4 hours (anephric patients) 5, 6:
For CrCl ≥30 mL/min:
- Use standard adult doses without adjustment 1, 5
- Monitor for accumulation if borderline (30-50 mL/min range)
For CrCl <30 mL/min:
- Reduce dose proportionally to reduced renal function 5
- Loading dose remains unchanged (based on body weight)
- Maintenance dose and interval must be extended 6, 7
- Example: If CrCl is 15 mL/min (15% of normal), reduce maintenance dose to approximately 15% of standard or extend intervals proportionally
The pharmacokinetic relationship is: Ke = 0.0766 + 0.0060 × CrCl, where Ke is the elimination rate constant 7. This allows precise individualization when CrCl is known.
Safety Considerations Specific to Elderly
Cephalexin is substantially excreted by the kidney, and elderly patients face greater risk of toxic reactions with impaired renal function 1. However, the drug demonstrates excellent safety when appropriately dosed:
- No clinically significant biochemical changes in elderly cohorts 3
- Low incidence of adverse effects (7% in geriatric studies, generally mild) 2
- No drug interactions reported with concurrent medications in elderly 3
- Minimal GI disturbance due to upper intestinal absorption 5
Rare but Serious Risk
Acute interstitial nephritis can occur, though rarely reported with cephalexin 8. Monitor for unexplained acute kidney injury during treatment.
Drug Interactions Requiring Attention
Metformin interaction: Cephalexin increases metformin exposure by 34% (Cmax) and 24% (AUC) through inhibition of renal tubular secretion 1. Monitor glucose closely and consider metformin dose reduction in elderly diabetics on both medications.
Probenecid: Inhibits cephalexin renal excretion, requiring dose reduction 1.
Practical Implementation
- Calculate CrCl or eGFR before prescribing—do not rely on serum creatinine alone
- If CrCl ≥30 mL/min: Use standard dosing (250-500 mg every 6-12 hours depending on infection)
- If CrCl <30 mL/min: Reduce maintenance dose proportionally or extend intervals; consider nephrology consultation for precise adjustment
- Monitor renal function during therapy, especially if baseline CrCl 30-60 mL/min
- Adjust metformin if co-prescribed
- Treatment duration: 7-14 days for cystitis, 10 days minimum for streptococcal infections 1
The evidence demonstrates that with appropriate renal assessment and dose adjustment, cephalexin remains highly effective and safe in elderly populations, with clinical outcomes matching younger patients 2.